Objective: The objectives of the study were to clarify the correlation between the expression of secreted protein acidic and rich in cysteine (SPARC) and HPV-status, and to determine the prognostic value of SPARC-expression in oropharyngeal squamous cell carcinoma (OPSCC) patients.
Introduction
Infection with high-risk human papillomavirus (HPV) has been etiologically linked to the development of head and neck squamous cell carcinomas, particularly carcinomas that arise in the oropharyngeal region. Patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) are characterized by an epidemiologic, demographic, and clinical profile that deviates from that of HPV-negative patients [1] . The most important difference is related to the prognosis, which is markedly better for patients with HPV-positive tumors compared to their HPV-negative counterparts [2] .
To date, OPSCC patients have presented with few prognostic markers targetable for improving prevention and treatment strategies. The HPV-status is closely associated with the prognosis of OPSCC patients and there is significant heterogeneity in outcomes of HPV-negative OPSCC patients [3] . However, no other reliable biomarkers have been found.
If new biomarkers, that can help determine the prognosis and survival of OPSCC patients, can be detected, they may help avoid both over-and under-treatment of OPSCC patients, resulting in improvements in the survival and quality of life of patients with this disease.
Secreted protein acidic and rich in cysteine (SPARC) has attracted marked interest as a tumor-associated protein for its diverse actions and complex functions. The increased expression of SPARC is associated with a highly aggressive tumor phenotype in melanomas 6 and gliomas, as supported by previous functional studies [4] , [5] , [6] , [7] . However, other studies reported that SPARC acts as a tumor suppressor in pancreatic adenocarcinoma, acute myeloid leukemia, and ovarian and colorectal carcinomas [8] , [9] , [10] , [11] . Actually, recent studies revealedthat SPARC mediates the interaction between cells and the extracellular environment as a matricellular protein, and upregulating its expression enhances chemosensitivity [12] . Functions of SPARC are elucidated in other cancers, but there are no report about relations between OPSCC and SPARC, and viral carcinogenesis and SPARC. The role of SPARC-expression in OPSCC remains to be clarified.
Here, we examined the expression of SPARC protein in OPSCC tissues. The purposes of the current study were to explore the correlation between SPARC-expression and the HPV-status, and to determine the prognostic value of SPARC-expression.
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Materials and Methods
Patients and tissue samples.
Fifty-three specimens were obtained from patients with OPSCC who underwent curative treatment such as surgery and/or radiotherapy with or without chemotherapy at Kanazawa University Hospital between 1991 and 2012. All specimens were fixed in 10% neutral formalin and embedded in paraffin, and then clinically and histopathologically diagnosed. All patients were staged according to the TNM staging system [13] based on initial radiologic imaging evaluation and endoscopic observation. The follow-up deadline was January 2014. The survival time was counted from the date of starting definitive therapy to the follow-up deadline or date of death, which was primarily caused by carcinoma recurrence or metastasis. All patients signed a letter of informed consent approved by our Institutional Ethics Committee (no. 1666).
All specimens were used to extract DNA for HPV detection using the polymerase chain reaction (PCR), and we also performed p16 immunohistochemistry. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor specimens using a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). Sixteen HPV genotypes (genotypes 6, 11, 16, 18, 30, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 66) were detected by multiple PCR in a single tube. The details of the procedures are described elsewhere [14] . We defined the specimen as HPV-positive 8 when both HPV DNA and p16-staining were positive.
Immunohistochemical analysis
Consecutive 4-μm sections were cut from each block. Immunohistochemical staining was performed as described previously [15] , [16] . The following primary antibodies were used: monoclonal antibodies for SPARC (dilution 1:200; SantaCruz, USA) derived from rabbits and p16 (dilution 1:100; SantaCruz, USA) derived from mice. The specificities of staining were confirmed using non-immune serum instead of the primary antibodies as negative controls. The degree of immunostaining was reviewed and scored independently by two observers (S.Y. and N.W.) based on the proportion of positively stained tumor cells and intensity of staining. For SPARC evaluation [16] , the tumor cell proportion was scored as follows: 0 (≤ 5% positive tumor cells), 1 (6-25% positive tumor cells), 2 (26-50% positive tumor cells), and 3 (> 51% positive tumor cells). The staining intensity was graded according to the following criteria: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown). The staining index (SI) was calculated as the product of the staining intensity score and proportion of positive tumor cells, with scores from 0 to 9 (0, 1, 2, 3, 4, 6, and 9). The cut-off values for high and low expression levels were chosen based on measures of heterogeneity using the log-rank test with respect to overall 9 survival. Optimal cut-off values were defined as follows: SI of ≥ 4 was used to define tumors with high SPARC-expression, and SI of ≤ 3 was used to indicate low SPARC-expression. For p16 evaluation, the sections were evaluated as p16-positive only when tumor cells were diffusely stained.
Statistical analysis
All statistical analyses were conducted using SPSS 19.0 software (IBM, Armonk, NY, USA). Data were analyzed using Fisher's exact t-test. Survival curves were estimated using the Kaplan-Meier method, and the log-rank test was used to investigate differences between the curves. Multivariate analysis using the Cox proportional hazards regression model was carried out to assess the prognostic value of each of the patients' characteristics. Significance was set at a p-value less than 0.05.
Results
Expression of SPARC and p16 in OPSCC tissues ( Fig. 1) High-expression of SPARC protein was detected in 25 (47.2%) tumors, and low-expression was detected in 28 (52.8%) tumors. SPARC protein was mainly localized in the cytoplasm of tumor cells and some stromal cells ( Fig. 1A, B ). Some stromal cells were constitutively positive, even if the tumor cells were stained negative (Fig.1C ). Twenty-eight and twenty-five cases were classified as SPARC-Low (Score 0, 3 cases; Score 1, 1 case; Score 2, 14 cases; and Score 3, 10 cases) and SPARC-High (Score 4, 2 cases; Score 6, 11 cases; and Score 9, 12 cases), respectively.
The 28 tumors were categorized as p16-positive, among which high-risk HPV-DNA was positive in 22 patients (41.5％), all of which were HPV type 16-positive. We confirmed that all 22 HPV-DNA-positive tumors were also p16-positive ( Fig. 1D ). Thus, 22 of the 53 OPSCCs were classified as HPV-related OPSCC.
Correlation between patients' demographic characteristics and the HPV-status (Table 1) The HPV-positive and HPV-negative OPSCC patients with respect to several clinical features are presented in Table 1 . Fifty-three surgical tissues and diagnostic biopsies from OPSCC patients, 22 HPV-positive and 31 HPV-negative, were available for our analysis. The 11 mean period of follow-up was 27 months (ranging from 2-100 months). In HPV-positive patients, the nodal status had significantly progressed (p = 0.0475). There was no significant correlation between the HPV-status and SPARC-expression (P=0.7280). (Table 2) The SPARC-High and SPARC-Low OPSCC patients with respect to several clinical factors are presented in Table 2 . No significant correlations were found between any analyzed demographic factors.
Correlation between patients' demographic characteristics and the SPARC-expression
Ten out of 28 SPARC-Low patients relapsed, among which 6 patients (60.0%) were salvaged by surgery. On the other hand, SPARC-High patients were prone to relapse (14 out of 25 patients, 56.0%) and salvage was difficult (only 21.4% of patients were salvaged).
Cox proportional hazards survival analysies (Tables 3, 4)
Univariate Cox proportional hazards regression analysis revealed that the HPV-status and SPARC-expression were significant prognostic indicators in patients with OPSCC in terms of the overall survival (OS) (p < 0.05) ( Table 3 ). These two parameters were further examined with multivariate analysis. After multivariate adjustment, high SPARC-expression remained a powerful poor prognostic indicator (p = 0.012, HR = 5.125) independent of HPV infection (p = 0.021, HR = 0.173).
Regarding disease-free survival (DFS), univariate Cox proportinal hazards regression analysis revealed that the HPV-status and N-factor were significant prognostic indicators of DFS (p < 0.05) ( Table 4 ). SPARC-expression was not a significant predictor of DFS. After multivariate adjustment, only HPV infection was a significant predictor (p = 0.022, HR = 0.302) ( Table 4 ).
Survival analyses in HPV-negative and HPV-positive patients in relation to the SPARC-expression level (Fig 2) Kaplan-Meier analyses of the 53 OPSCC patients were carried out. OS and DFS were determined on the basis of the HPV-status and SPARC-expression. Among all 53 patients, the 5-year OS rates differed significantly between HPV-positive and HPV-negative patients (Figure 2A ; p = 0.011) and between low and high SPARC-expression patients ( Figure 2B ; p = 0.006). After stratification by the HPV-status, SPARC-expression remained a significant prognostic indicator in HPV-negative OPSCC patients, but was not a significant predictor in HPV-positive patients (Figure 2C, D) .
The disease-free survival rate was significantly more favorable in HPV-positive than
Discussion
Higher levels of SPARC-expression have been reported in breast cancer, melanoma, and glioblastoma patients [5] , [6] , [17] . Based on this pattern of expression, one would hypothesize a potential role of SPARC in tumor promotion or progression. However, lower levels of SPARC-expression have been found in other types of malignancy, such as ovarian, colorectal, and pancreatic cancers and acute myelogenous leukemia [8] , [9] , [18] . This pattern of decreased SPARC levels suggests an inhibitory role of SPARC in tumor progression. The possible clinical significance of SPARC expression has not been reported in OPSCC patients. Therefore, we investigated the relationships between immunohistochemical SPARC-expression and clinicopathologic parameters, including patient survival. High-expression of SPARC showed a significant correlation with poor OS.
In OPSCC patients, HPV-infection has accounted for a growing proportion of cases, particularly among the middle-aged population. Patients with HPV-positive OPSCC have a more favorable prognosis than HPV-negative patients [3] . Our results also support those of previous reports. It has been reported that aberrant DNA methylation, an important epigenetic mechanism for gene silencing, occurs in HPV-related carcinogenesis [18] , and that SPARC is transcriptionally down-regulated by its promoter hyper-methylation in some cancers. Therefore, we examined the association between the HPV-status and SPARC-expression in OPSCC tissues. However there was no significant correlation between the HPV-status and SPARC-expression. Next, we examined whether SPARC could be a In contrast to OS, SPARC-expression did not show a significant correlation with DFS.
The reason why SPARC-expression was not a prognostic indicator of DFS is considered to be that SPARC-High patients were inoperable at the time of relapse or could not be rescued by salvage surgery. In other words, SPARC-Low patients could be salvaged, so their OS rate was higher than that of SPARC-High patients. It has been reported that SPARC regulates cell-ECM signals which control cell invasion and migration [19] , and the formation of matrix metalloproteinases [20] . These roles of SPARC may have influenced the difference in salvage HPV-negative OPSCC patients (p = 0.011). B, The 5-year OS rate was significantly different between SPARC-Low and SPARC-High patients (p = 0.006). C, Within the HPV-positive stratum, SPARC-expression did not show a significant effect on OS (p = 0.137). D, Within the HPV-negative stratum, the SPARC-Low patients showed significantly more favorable OS than the SPARC-High patients (p = 0.014). E, The DFS curve of OPSCC patients with a different HPV-status was significantly different between HPV-positive and HPV-negative patients (p = 0.003). F, The DFS curve with different SPARC-expression levels did not show 22 a significant difference (p = 0.157). G and H, In both the HPV-positive and HPV-negative stratum, SPARC-expression did not show any significant correlation with DFS (p = 0.182 and p = 0.420). 
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